Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Kamin

Cardiovascular Disease Olympia Fields, IL Doctor of Osteopathy

NPI 1043203862 CMS profile 46792

3800 W 203Rd St Ste 204, Olympia Fields, IL 60461

Open in the dashboard

General payments

$30,795

564 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Kamin of Olympia Fields, IL is reported in the CMS Open Payments database as having received $30,795 across 564 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,386 111
2024 General $7,632 115
2023 General $2,500 90
2022 General $2,362 99
2021 General $1,455 57
2020 General $582 29
2019 General $878 63

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Kamin
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Matthew Kamin were reported at $15,386. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Matthew Kamin Cardiovascular Disease median Middle half National median
2019 $878 $450 $127–$1,392 $163
2020 $582 $242 $77–$751 $114
2021 $1,455 $335 $101–$1,037 $132
2022 $2,362 $395 $121–$1,211 $149
2023 $2,500 $443 $136–$1,283 $160
2024 $7,632 $450 $136–$1,323 $164
2025 $15,386 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $19,400 67 payments
  2. Janssen Pharmaceuticals, Inc $1,811 82 payments
  3. E.R. Squibb & Sons, L.L.C. $1,400 45 payments
  4. Novartis Pharmaceuticals Corporation $1,393 94 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $1,355 39 payments
  6. AstraZeneca Pharmaceuticals LP $761 25 payments
  7. Boston Scientific Corporation $657 25 payments
  8. Pfizer Inc. $586 32 payments
  9. Merck Sharp & Dohme Corporation $543 19 payments
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $502 35 payments
  11. Other $2,386 101 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,286 10 payments
  2. Food and Beverage $13,282 552 payments
  3. Travel and Lodging $2,226 2 payments
Products named General payments · program years 2019–2025
  1. REPATHA Cardiovascular $13,437 24 payments
  2. Repatha Cardiology $5,964 43 payments
  3. XARELTO $1,811 82 payments
  4. CAMZYOS $979 26 payments
  5. JARDIANCE $870 23 payments
  6. VERQUVO $757 25 payments
  7. LEQVIO $678 44 payments
  8. ENTRESTO $663 47 payments
  9. WATCHMAN Access System $657 25 payments
  10. LifeVest $502 35 payments
  11. Other $5,392 247 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 58 drugs

Part D claims

10,290

Median for Cardiology: 2,533

Drug cost

$2,835,777

Median for Cardiology: $485,213

Branded share of claims

29.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 500 $616,251
Repatha Sureclick Evolocumab Brand 701 $524,409
Entresto Sacubitril/Valsartan Brand 322 $443,949
Eliquis Apixaban Brand 307 $387,972
Vyndamax Tafamidis Brand 12 $276,077
Jardiance Empagliflozin Brand 146 $178,460
Praluent Pen Alirocumab Brand 211 $143,212
Farxiga Dapagliflozin Propanediol Brand 40 $34,064
Ezetimibe Generic 990 $26,146
Nexlizet Bempedoic Acid/Ezetimibe Brand 25 $24,060

The 10 drugs with the highest cost, of 58 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$216,565

Of which drugs: $8,127

Medicare patients

1,050

Average age 75

Services billed

5,420

524 women, 526 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 51%
Arthritis 51%
Heart failure 35%
Diabetes 33%
Atrial fibrillation 27%
Chronic kidney disease 21%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, octafluoropropane microspheres, per ml Q9956 Office 63 198 $6,201
Injection, regadenoson, 0.1 mg J2785 Office 74 296 $1,545

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
  • Amgen Inc. $5,118
$5,118 701 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $321
$321 146 —
VERQUVO
  • Merck Sharp & Dohme Corporation $214
$214 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $182
$182 — —
Inpefa
  • Lexicon Pharmaceuticals, Inc. $125
$125 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record